Liebling Dustin B, Cordova Emmanuel, Deng Gary, McKoy June M
Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA.
Cancer Treat Res. 2019;171:37-45. doi: 10.1007/978-3-319-43896-2_3.
With the increase in utilization of alternative medications to manage cancer treatment-related side effects, pharmacovigilance of alternative drug therapies, specifically herbal supplements, has become of increasing importance in the oncologic setting. This chapter focuses on the pharmacovigilance of herbal supplements in the setting of cancer drug therapy and explores national and international drug policies that have been employed to mitigate adverse herbal supplement events (AHEs). This chapter examines common drug-herbal supplement interactions, discusses the mechanisms behind these interactions, and investigates several common pharmacovigilance reporting methods clinicians can use to report adverse events. This chapter will also describe policies and strategies that can be employed to monitor use of these alternative drug therapies, and examines global harmonization efforts to reduce AHEs in the cancer setting. The safety of herbal medicines has emerged as an international public health priority, and we explore how oncology providers may directly apply the knowledge garnered herein to help guide their clinical management of oncology patients utilizing alternative medications.
随着用于管理癌症治疗相关副作用的替代药物使用增加,替代药物疗法,特别是草药补充剂的药物警戒在肿瘤学环境中变得越来越重要。本章重点关注癌症药物治疗背景下草药补充剂的药物警戒,并探讨已用于减轻不良草药补充剂事件(AHEs)的国家和国际药物政策。本章研究常见的药物 - 草药补充剂相互作用,讨论这些相互作用背后的机制,并研究临床医生可用于报告不良事件的几种常见药物警戒报告方法。本章还将描述可用于监测这些替代药物疗法使用情况的政策和策略,并探讨在癌症环境中减少AHEs的全球协调努力。草药的安全性已成为国际公共卫生优先事项,我们探讨肿瘤学提供者如何直接应用在此获得的知识,以帮助指导他们对使用替代药物的肿瘤学患者的临床管理。